Jyong Biotech (MENS) Non-Current Debt (2024 - 2025)
Jyong Biotech's (MENS) quarterly Non-Current Debt came in at $447000.0 in Q4 2025, down 78.0% year-on-year from $2.0 million in Q4 2024, and down 77.02% quarter-over-quarter from $1.9 million in Q2 2025.
Jyong Biotech (MENS) Non-Current Debt (2024 - 2025) Analysis & Trends
Jyong Biotech's Non-Current Debt history runs 2 years deep, the most recent figure standing at $447000.0 for Q4 2025.
- On a quarterly basis, Non-Current Debt fell 78.0% year-over-year to $447000.0 in Q4 2025; TTM through Dec 2025 was $447000.0, a 78.0% decrease from a year earlier, with the FY2025 full-year figure at $447000.0, down 78.0% from the prior year.
- Non-Current Debt fell to $447000.0 in Q4 2025 per MENS's latest filing, from $1.9 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $2.0 million in Q4 2024 and bottomed at $447000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Jyong Biotech | 197.86 Mn | 197.86 Mn | - | 447,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 447,000.00 |
| Jun 30, 2025 | 1.95 Mn |
| Dec 31, 2024 | 2.03 Mn |